Results 81 to 90 of about 58,715 (237)
Thalidomide does not interact with P-glycoprotein [PDF]
, 2018 Background: There is growing clinical interest in thalidomide for the treatment of various disorders due to its anti-inflammatory, immunomodulatory, and anti-angiogenic properties. In numerous clinical trials thalidomide is used as an adjunct to standard
Drewe, Juergen +2 more
core
"The legacy of thalidomide" - A multidisciplinary meeting held at the University of York, United Kingdom, on September 30, 2016 : A multidisciplinary meeting held at the University of York, UK on September 30, 2016 [PDF]
, 2017 BACKGROUND: Between 1957 and 1962 thalidomide was used as a nonaddictive, nonbarbiturate sedative that also was successful in relieving the symptoms of morning sickness in early pregnancy.
Beedie +18 more
core +2 more sources
JEADV Clinical Practice, EarlyView.ABSTRACT Background Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Objectives Patients with SMX receiving high‐dose intravenous IVIg therapy were included to assess validity of the double modified ...
Julia K. Winkler, Alexander H. Enk
wiley +1 more source
Clinical Case Reports, 2019 Thalidomide is often used for the management of refractory gastrointestinal angiodysplasia (GIAD). The tolerance, toxic profile, and compliance of thalidomide are dose‐dependent.
Harish Patel +6 more
doaj +1 more source
Paediatric developmental safety and the ICH E11A extrapolation of safety
British Journal of Clinical Pharmacology, EarlyView.
Gilbert J. Burckart +6 more
wiley +1 more source
Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone
JEADV Clinical Practice, EarlyView.ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri +2 more
wiley +1 more source
Thalidomide in dermatology: Revisited
Indian Journal of Dermatology, 2015 The use of thalidomide in relation to dermatology is well- known and enough data is available in the literature about various aspects of thalidomide.
Iffat Hassan +2 more
doaj +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis associated with systemic inflammatory diseases and malignancy. Although biologic therapies demonstrate efficacy in PG, the extent of their real‐world use remains incompletely characterized.
Rhiannon Grange +4 more
wiley +1 more source
Wellcome Witnesses to Twentieth Century Medicine: Volume 1 [PDF]
, 1998 Annotated and edited transcript of four Witness Seminars. Introduction by E M Tansey First published by the Wellcome Trust, 1997. ©The Trustee of the Wellcome Trust, London, 1997.In Volume One (Occasional Publication no.
Catterall, PP +4 more
core
‘From the Fields Into the Bars’: The Story of Israel's First Transgender Novel, The Cut (1977)
Gender &History, EarlyView.ABSTRACT In 1977, an Israeli transgender woman, Judy Spotheim, published an autobiographical novel entitled The Cut. It describes the emergence of a trans community in the commercial‐sex areas of Tel Aviv‐Jaffa, hoping to humanise trans women (coccinelles). This article is the first to study the novel and present a biography of Spotheim.
Gil Engelstein, Iris Rachamimov
wiley +1 more source